Cagrilintide
also known as AM833, CagriSema (combination form)
Long-acting amylin receptor agonist studied in combination with semaglutide (CagriSema) for obesity and type 2 diabetes. Acts centrally to induce satiety, suppress prandial glucagon, and reduce food intake. Phase 3 trials show 7.5% greater weight loss versus semaglutide monotherapy. Demonstrates dual AMYR/calcitonin-receptor agonism with extended half-life enabling once-weekly subcutaneous dosing.
At a glance
SQ · Once Weekly
Primary target — Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexes [bailey-2026].
Pathway — AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagon [bailey-2026].
Downstream effect — Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic control [bailey-2026][yamauchi-2026].
Origin — Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosing [bailey-2026].
Feedback intact — Yes — acts via physiological amylin pathways.
| Parameter | Value |
|---|---|
| Standard dose (combination) | Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema) [yamauchi-2026]Phase 3 REDEFINE 5 trial dosing. |
| Monotherapy dosing | Dose-dependent, under investigationMonotherapy trials reported in meta-analysis. |
| Frequency | Once weekly (subcutaneous) [bailey-2026]Long-acting formulation. |
| Evidence basis | Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545) [yamauchi-2026][ahmed-2026] |
| Duration | 26–52 weeks in trials [yamauchi-2026] |
| Route | Subcutaneous injection [bailey-2026] |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Phase 3 RCT (REDEFINE 5) · Meta-analysis of 3 RCTs (n=3545) · 26–52 weeks [yamauchi-2026][ahmed-2026]
| Outcome | Finding |
|---|---|
| Weight loss vs semaglutide | 7.47% greater percentage weight loss [ahmed-2026]CagriSema combination vs semaglutide monotherapy (meta-analysis). |
| Absolute weight change | Significantly greater absolute weight reduction [ahmed-2026]Mean difference favoring combination therapy. |
| Mechanism | Central satiety induction [bailey-2026] |
| BMI reduction | Significant BMI reduction vs comparator [ahmed-2026] |
| Glycemic benefit | Reduced fasting glucose and HbA1c [ahmed-2026]Synergistic effect with semaglutide in combination. |
| Lipid effects | Improvements in total cholesterol, LDL-C, HDL-C, VLDL-C, triglycerides [ahmed-2026] |
| Body composition | Predominant fat loss with weight reduction |
| Mitochondrial function | In vitro effects on skeletal muscle mitochondria under metabolic stress conditions [old-2026]C2C12 myotube study; clinical relevance under investigation. |
| Combination rationale | Multi-pathway approach: amylin (satiety) + GLP-1 (incretin) [lempesis-2026] |
| Key publications | REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026 [yamauchi-2026][ahmed-2026][bailey-2026] |
- — Hypersensitivity to cagrilintide or formulation components
- — Severe gastrointestinal disease
- — History of pancreatitis (incretin-based therapy consideration)
- 01Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule. [bailey-2026]
- 02Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism. [yamauchi-2026][bailey-2026]
- 03Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
- 04Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
- 05Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes. [pardali-2026]
Sources
of 64 rendered claims carry a resolvable citation.
- [ahmed-2026]Ahmed 2026 — Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
journal, 2026 - [bailey-2026]Bailey 2026 — Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
journal, 2026 - [lempesis-2026]Lempesis 2026 — Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
journal, 2026 - [old-2026]Old 2026 — Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
journal, 2026 - [pardali-2026]Pardali 2026 — New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.
journal, 2026 - [yamauchi-2026]Yamauchi 2026 — Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
journal, 2026